TapImmune Inc. (TPIV) Releases Positive Interim Data On Phase I Clinical Trial In HER2/Neu+ Breast Cancer
3/3/2014 9:19:35 AM
SEATTLE--(BUSINESS WIRE)--TapImmune Inc. (OTCQB:TPIVD) is pleased to report that analysis of the interim data from the first set of patients in a Phase I clinical trial show that each of the patients have raised specific T-cell immune responses against a set of naturally processed HER2/neu Class II antigenic epitopes. The Phase I trial is being carried at the Mayo Clinic, Rochester, MN.
Help employers find you! Check out all the jobs and post your resume.
comments powered by